What is the projected market valuation for the US controlled release-drug-delivery market by 2035?

The projected market valuation for the US controlled release-drug-delivery market is $16.0 Billion by 2035. Read More

What was the market valuation for the US controlled release-drug-delivery market in 2024?

The market valuation for the US controlled release-drug-delivery market was $5.5 Billion in 2024. Read More

What is the expected CAGR for the US controlled release-drug-delivery market during the forecast period 2025 - 2035?

The expected CAGR for the US controlled release-drug-delivery market during the forecast period 2025 - 2035 is 10.19%. Read More

Which application segment is projected to have the highest valuation by 2035?

The Diabetes application segment is projected to reach $3.5 Billion by 2035. Read More

What are the key players in the US controlled release-drug-delivery market?

Key players in the US controlled release-drug-delivery market include Johnson & Johnson, Roche, Bristol-Myers Squibb, Novartis, Pfizer, Merck & Co., AbbVie, and Gilead Sciences. Read More

Which formulation type is expected to show the most growth by 2035?

The Oral formulation type is expected to grow to $6.0 Billion by 2035. Read More

What is the projected valuation for Polymer-Based Systems by 2035?

The projected valuation for Polymer-Based Systems is $4.8 Billion by 2035. Read More

How does the market for Injectable systems compare to Oral systems by 2035?

By 2035, the market for Injectable systems is projected to reach $3.2 Billion, whereas Oral systems are expected to reach $6.0 Billion. Read More

What is the expected market size for hospitals as an end-use segment by 2035?

The expected market size for hospitals as an end-use segment is $4.8 Billion by 2035. Read More

Which technology segment is anticipated to have the lowest valuation by 2035?

The Inorganic Nanoparticle Systems technology segment is anticipated to have the lowest valuation at $2.2 Billion by 2035. Read More

US Controlled Release Drug Delivery Market

ID: MRFR/Pharma/15128-HCR

100 Pages

Satyendra Maurya

Last Updated: April 06, 2026

US Controlled Release Drug Delivery Market Research Report: Size, Share, Trend Analysis By Applications (Oncology, Cardiology, Diabetes, Neurology, Autoimmune Diseases), By Technology (Polymer-Based Systems, Liposome-Based Systems, Inorganic Nanoparticle Systems, Monoclonal Antibodies, Microsphere Systems), By Formulation Type (Injectable, Oral, Transdermal, Inhalation, Implantable) and By End Use (Hospitals, Homecare Settings, Research Laboratories, Pharmaceutical Companies, Specialty Clinics) - Growth Outlook & Industry Forecast 2025 To 2035

US Controlled Release Drug Delivery Market Infographic

Summary Table of Contents Segmentation Download PDF

Certified Researchers

Customize Report

1 SECTION I: EXECUTIVE SUMMARY AND KEY HIGHLIGHTS
1. 1.1 EXECUTIVE SUMMARY
  1. 1.1.1 Market Overview
  2. 1.1.2 Key Findings
  3. 1.1.3 Market Segmentation
  4. 1.1.4 Competitive Landscape
  5. 1.1.5 Challenges and Opportunities
  6. 1.1.6 Future Outlook
2 SECTION II: SCOPING, METHODOLOGY AND MARKET STRUCTURE
1. 2.1 MARKET INTRODUCTION
  1. 2.1.1 Definition
  2. 2.1.2 Scope of the study
    1. 2.1.2.1 Research Objective
    2. 2.1.2.2 Assumption
    3. 2.1.2.3 Limitations
2. 2.2 RESEARCH METHODOLOGY
  1. 2.2.1 Overview
  2. 2.2.2 Data Mining
  3. 2.2.3 Secondary Research
  4. 2.2.4 Primary Research
    1. 2.2.4.1 Primary Interviews and Information Gathering Process
    2. 2.2.4.2 Breakdown of Primary Respondents
  5. 2.2.5 Forecasting Model
  6. 2.2.6 Market Size Estimation
    1. 2.2.6.1 Bottom-Up Approach
    2. 2.2.6.2 Top-Down Approach
  7. 2.2.7 Data Triangulation
  8. 2.2.8 Validation
3 SECTION III: QUALITATIVE ANALYSIS
1. 3.1 MARKET DYNAMICS
  1. 3.1.1 Overview
  2. 3.1.2 Drivers
  3. 3.1.3 Restraints
  4. 3.1.4 Opportunities
2. 3.2 MARKET FACTOR ANALYSIS
  1. 3.2.1 Value chain Analysis
  2. 3.2.2 Porter's Five Forces Analysis
    1. 3.2.2.1 Bargaining Power of Suppliers
    2. 3.2.2.2 Bargaining Power of Buyers
    3. 3.2.2.3 Threat of New Entrants
    4. 3.2.2.4 Threat of Substitutes
    5. 3.2.2.5 Intensity of Rivalry
  3. 3.2.3 COVID-19 Impact Analysis
    1. 3.2.3.1 Market Impact Analysis
    2. 3.2.3.2 Regional Impact
    3. 3.2.3.3 Opportunity and Threat Analysis
4 SECTION IV: QUANTITATIVE ANALYSIS
1. 4.1 Industrial Automation & Equipment, BY Application (USD Billion)
  1. 4.1.1 Oncology
  2. 4.1.2 Cardiology
  3. 4.1.3 Diabetes
  4. 4.1.4 Neurology
  5. 4.1.5 Autoimmune Diseases
2. 4.2 Industrial Automation & Equipment, BY Technology (USD Billion)
  1. 4.2.1 Polymer-Based Systems
  2. 4.2.2 Liposome-Based Systems
  3. 4.2.3 Inorganic Nanoparticle Systems
  4. 4.2.4 Monoclonal Antibodies
  5. 4.2.5 Microsphere Systems
3. 4.3 Industrial Automation & Equipment, BY Formulation Type (USD Billion)
  1. 4.3.1 Injectable
  2. 4.3.2 Oral
  3. 4.3.3 Transdermal
  4. 4.3.4 Inhalation
  5. 4.3.5 Implantable
4. 4.4 Industrial Automation & Equipment, BY End Use (USD Billion)
  1. 4.4.1 Hospitals
  2. 4.4.2 Homecare Settings
  3. 4.4.3 Research Laboratories
  4. 4.4.4 Pharmaceutical Companies
  5. 4.4.5 Specialty Clinics
5 SECTION V: COMPETITIVE ANALYSIS
1. 5.1 Competitive Landscape
  1. 5.1.1 Overview
  2. 5.1.2 Competitive Analysis
  3. 5.1.3 Market share Analysis
  4. 5.1.4 Major Growth Strategy in the Industrial Automation & Equipment
  5. 5.1.5 Competitive Benchmarking
  6. 5.1.6 Leading Players in Terms of Number of Developments in the Industrial Automation & Equipment
  7. 5.1.7 Key developments and growth strategies
    1. 5.1.7.1 New Product Launch/Service Deployment
    2. 5.1.7.2 Merger & Acquisitions
    3. 5.1.7.3 Joint Ventures
  8. 5.1.8 Major Players Financial Matrix
    1. 5.1.8.1 Sales and Operating Income
    2. 5.1.8.2 Major Players R&D Expenditure. 2023
2. 5.2 Company Profiles
  1. 5.2.1 Johnson & Johnson (US)
    1. 5.2.1.1 Financial Overview
    2. 5.2.1.2 Products Offered
    3. 5.2.1.3 Key Developments
    4. 5.2.1.4 SWOT Analysis
    5. 5.2.1.5 Key Strategies
  2. 5.2.2 Roche (CH)
    1. 5.2.2.1 Financial Overview
    2. 5.2.2.2 Products Offered
    3. 5.2.2.3 Key Developments
    4. 5.2.2.4 SWOT Analysis
    5. 5.2.2.5 Key Strategies
  3. 5.2.3 Bristol-Myers Squibb (US)
    1. 5.2.3.1 Financial Overview
    2. 5.2.3.2 Products Offered
    3. 5.2.3.3 Key Developments
    4. 5.2.3.4 SWOT Analysis
    5. 5.2.3.5 Key Strategies
  4. 5.2.4 Novartis (CH)
    1. 5.2.4.1 Financial Overview
    2. 5.2.4.2 Products Offered
    3. 5.2.4.3 Key Developments
    4. 5.2.4.4 SWOT Analysis
    5. 5.2.4.5 Key Strategies
  5. 5.2.5 Pfizer (US)
    1. 5.2.5.1 Financial Overview
    2. 5.2.5.2 Products Offered
    3. 5.2.5.3 Key Developments
    4. 5.2.5.4 SWOT Analysis
    5. 5.2.5.5 Key Strategies
  6. 5.2.6 Merck & Co. (US)
    1. 5.2.6.1 Financial Overview
    2. 5.2.6.2 Products Offered
    3. 5.2.6.3 Key Developments
    4. 5.2.6.4 SWOT Analysis
    5. 5.2.6.5 Key Strategies
  7. 5.2.7 AbbVie (US)
    1. 5.2.7.1 Financial Overview
    2. 5.2.7.2 Products Offered
    3. 5.2.7.3 Key Developments
    4. 5.2.7.4 SWOT Analysis
    5. 5.2.7.5 Key Strategies
  8. 5.2.8 Gilead Sciences (US)
    1. 5.2.8.1 Financial Overview
    2. 5.2.8.2 Products Offered
    3. 5.2.8.3 Key Developments
    4. 5.2.8.4 SWOT Analysis
    5. 5.2.8.5 Key Strategies
3. 5.3 Appendix
  1. 5.3.1 References
  2. 5.3.2 Related Reports
6 LIST OF FIGURES
1. 6.1 MARKET SYNOPSIS
2. 6.2 US MARKET ANALYSIS BY APPLICATION
3. 6.3 US MARKET ANALYSIS BY TECHNOLOGY
4. 6.4 US MARKET ANALYSIS BY FORMULATION TYPE
5. 6.5 US MARKET ANALYSIS BY END USE
6. 6.6 KEY BUYING CRITERIA OF INDUSTRIAL AUTOMATION & EQUIPMENT
7. 6.7 RESEARCH PROCESS OF MRFR
8. 6.8 DRO ANALYSIS OF INDUSTRIAL AUTOMATION & EQUIPMENT
9. 6.9 DRIVERS IMPACT ANALYSIS: INDUSTRIAL AUTOMATION & EQUIPMENT
10. 6.10 RESTRAINTS IMPACT ANALYSIS: INDUSTRIAL AUTOMATION & EQUIPMENT
11. 6.11 SUPPLY / VALUE CHAIN: INDUSTRIAL AUTOMATION & EQUIPMENT
12. 6.12 INDUSTRIAL AUTOMATION & EQUIPMENT, BY APPLICATION, 2024 (% SHARE)
13. 6.13 INDUSTRIAL AUTOMATION & EQUIPMENT, BY APPLICATION, 2024 TO 2035 (USD Billion)
14. 6.14 INDUSTRIAL AUTOMATION & EQUIPMENT, BY TECHNOLOGY, 2024 (% SHARE)
15. 6.15 INDUSTRIAL AUTOMATION & EQUIPMENT, BY TECHNOLOGY, 2024 TO 2035 (USD Billion)
16. 6.16 INDUSTRIAL AUTOMATION & EQUIPMENT, BY FORMULATION TYPE, 2024 (% SHARE)
17. 6.17 INDUSTRIAL AUTOMATION & EQUIPMENT, BY FORMULATION TYPE, 2024 TO 2035 (USD Billion)
18. 6.18 INDUSTRIAL AUTOMATION & EQUIPMENT, BY END USE, 2024 (% SHARE)
19. 6.19 INDUSTRIAL AUTOMATION & EQUIPMENT, BY END USE, 2024 TO 2035 (USD Billion)
20. 6.20 BENCHMARKING OF MAJOR COMPETITORS
7 LIST OF TABLES
1. 7.1 LIST OF ASSUMPTIONS
7.1.1
1. 7.2 US MARKET SIZE ESTIMATES; FORECAST
  1. 7.2.1 BY APPLICATION, 2025-2035 (USD Billion)
  2. 7.2.2 BY TECHNOLOGY, 2025-2035 (USD Billion)
  3. 7.2.3 BY FORMULATION TYPE, 2025-2035 (USD Billion)
  4. 7.2.4 BY END USE, 2025-2035 (USD Billion)
2. 7.3 PRODUCT LAUNCH/PRODUCT DEVELOPMENT/APPROVAL
7.3.1
1. 7.4 ACQUISITION/PARTNERSHIP
7.4.1

Certified Researchers

Customize Report

US Industrial Automation & Equipment Market Segmentation

Industrial Automation & Equipment By Application (USD Billion, 2025-2035)

Oncology
Cardiology
Diabetes
Neurology
Autoimmune Diseases

Industrial Automation & Equipment By Technology (USD Billion, 2025-2035)

Polymer-Based Systems
Liposome-Based Systems
Inorganic Nanoparticle Systems
Monoclonal Antibodies
Microsphere Systems

Industrial Automation & Equipment By Formulation Type (USD Billion, 2025-2035)

Injectable
Oral
Transdermal
Inhalation
Implantable

Industrial Automation & Equipment By End Use (USD Billion, 2025-2035)

Hospitals
Homecare Settings
Research Laboratories
Pharmaceutical Companies
Specialty Clinics

Customer Stories

“This is really good guys. Excellent work on a tight deadline. I will continue to use you going forward and recommend you to others. Nice job”

Noah Malgeri Co-Founder

“Thanks. It’s been a pleasure working with you, please use me as reference with any other Intel employees.”

Joseph Aguayo Sales Operations & Pricing Manager

“Thanks for sending the report it gives us a good global view of the Betaïne market.”

Peter Groot koerkamp Account and Business Manager

“Thank you, this will be very helpful for OQS.”

La Terria Dodd Program Support Specialist

“We found the report very insightful! we found your research firm very helpful. I'm sending this email to secure our future business.”

Younghwan Choi Senior Retail Manager

“I am very pleased with how market segments have been defined in a relevant way for my purposes (such as "Portable Freezers & refrigerators" and "last-mile"). In general the report is well structured. Thanks very much for your efforts.”

Mark Irwin Management Consultant

“I have been reading the first document or the study, ,the Global HVAC and FP market report 2021 till 2026. Must say, good info! I have not gone in depth at all parts, but got a good indication of the data inside!”